Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Astrazeneca Plc Spons Adr / Equity Bottom-Up

<ul><li>AstraZeneca's recent earnings report for the first nine months and Q3 2025 underscores the company's ongoing momentum and commitment to innovation within its pharmaceutical pipeline.</li><li>Total revenue increased by 11%, driven by robust demand for its innovative medicines.</li><li>The company reported core EPS growth of 15%, signaling strong operational performance.</li></ul>

AstraZeneca's recent earnings report for the first nine months and Q3 2025 underscores the company's ongoing momentum and commitment to innovation within its pharmaceutical pipeline.Total revenue increased by 11%, driven by robust demand for its innovative medicines.The company reported core EPS growth of 15%, signaling strong operational performance.

AstraZeneca: An Insight Into The Growth Potential Of Imfinzi

<ul><li>AstraZeneca’s stock gained after a landmark drug pricing agreement with the White House, marking a significant policy pivot for the pharmaceutical industry.</li><li>As part of the deal, AstraZeneca will provide all its prescription medications to Medicaid at “most favored nation” prices—effectively matching the lowest global rates.</li><li>Additionally, the company will participate in the new TrumpRx.com platform, offering consumers direct access to discounted drugs.</li></ul>

AstraZeneca’s stock gained after a landmark drug pricing agreement with the White House, marking a significant policy pivot for the pharmaceutical industry.As part of the deal, AstraZeneca will provide all its prescription medications to Medicaid at “most favored nation” prices—effectively matching the lowest global rates.Additionally, the company will participate in the new TrumpRx.com platform, offering consumers direct access to discounted drugs.

AstraZeneca’s White House Deal: Policy Relief, Margin Risks & A $50 Billion U.S. Bet!

<ul><li>AstraZeneca, a prominent global biopharmaceutical company, reported its financial results for the first half of 2025, showcasing continued growth and development across its portfolio.</li><li>The company's total revenue increased by 11%, fueled by robust demand for its innovative medicines, notably in oncology and biopharmaceuticals.</li><li>Core Earnings Per Share (EPS) rose by 17%, reflecting the company's focus on its pipeline investments alongside efforts to optimize operating leverage.</li></ul>

AstraZeneca, a prominent global biopharmaceutical company, reported its financial results for the first half of 2025, showcasing continued growth and development across its portfolio.The company's total revenue increased by 11%, fueled by robust demand for its innovative medicines, notably in oncology and biopharmaceuticals.Core Earnings Per Share (EPS) rose by 17%, reflecting the company's focus on its pipeline investments alongside efforts to optimize operating leverage.

AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments?

<ul><li>AstraZeneca has reported its first quarter 2025 financial results, revealing a robust performance marked by a 10% increase in total revenue.</li><li>The pharmaceutical giant's growth was driven by rising demand for its innovative medicines, with core operating profit up by 12% and core EPS rising by 21%.</li><li>This performance was partially bolstered by favorable tax settlements.</li></ul>

AstraZeneca has reported its first quarter 2025 financial results, revealing a robust performance marked by a 10% increase in total revenue.The pharmaceutical giant's growth was driven by rising demand for its innovative medicines, with core operating profit up by 12% and core EPS rising by 21%.This performance was partially bolstered by favorable tax settlements.

<ul><li>AstraZeneca presented robust financial outcomes for the year 2024, achieving a total revenue growth of 21% and an increase in core earnings per share (EPS) of 19%.</li><li>This reflects solid demand across its diverse portfolio and geographical footprint.</li><li>The company's strategic focus led to numerous pipeline advancements, notably nine high-value pivotal trial readouts that signify future growth potential, with an ambition to introduce 20 new medicines by 2030.</li></ul>

AstraZeneca presented robust financial outcomes for the year 2024, achieving a total revenue growth of 21% and an increase in core earnings per share (EPS) of 19%.This reflects solid demand across its diverse portfolio and geographical footprint.The company's strategic focus led to numerous pipeline advancements, notably nine high-value pivotal trial readouts that signify future growth potential, with an ambition to introduce 20 new medicines by 2030.

AstraZeneca: A Tale Of Oncology, Rare Diseases & Big Acquisitions!

United Kingdom

AstraZeneca PLC is a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas: Gastrointestinal, Oncology, Cardiovascular, Respiratory, Central Nervous System, Pain Control, Anaesthesia, and Infection.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Astrazeneca Plc Spons Adr (AZN US)

AstraZeneca: An Insight Into The Growth Potential Of Imfinzi

AstraZeneca's recent earnings report for the first nine months and Q3 2025 underscores the company's ongoing momentum and commitment to innovation...

Baptista Research

AstraZeneca’s White House Deal: Policy Relief, Margin Risks & A $50 Billion U.S. Bet!

AstraZeneca’s stock gained after a landmark drug pricing agreement with the White House, marking a significant policy pivot for the pharmaceutical...

Baptista Research

AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments?

AstraZeneca, a prominent global biopharmaceutical company, reported its financial results for the first half of 2025, showcasing continued growth...

Baptista Research

AstraZeneca: Pipeline Diversification

AstraZeneca has reported its first quarter 2025 financial results, revealing a robust performance marked by a 10% increase in total revenue. The...

Baptista Research

AstraZeneca: A Tale Of Oncology, Rare Diseases & Big Acquisitions!

AstraZeneca presented robust financial outcomes for the year 2024, achieving a total revenue growth of 21% and an increase in core earnings per...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)